A carregar...
Efficacy and safety of lapatinib and trastuzumab for HER2-positive breast cancer: a systematic review and meta-analysis of randomised controlled trials
OBJECTIVES: The anti-HER2 monoclonal antibody trastuzumab and the tyrosine kinase inhibitor lapatinib have complementary mechanisms of action and synergistic antitumour actively in models of HER2-positive breast cancer. However, the efficacy of trastuzumab in combination with lapatinib remains contr...
Na minha lista:
| Publicado no: | BMJ Open |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5353336/ https://ncbi.nlm.nih.gov/pubmed/28289045 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2016-013053 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|